We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung cancer is made available via the Cancer Drugs Fund (CDF).